Three chewable tablets contain: 4Life Tri-Factor brand Formula 600 mg: Transfer Factor XF brand Patented Concentrate of Transfer Factor and Other Natural Components from Cow Colostrum and Egg Yolk, NanoFactor brand Proprietary Concentrate of Nano-filtered Cow Colostrum . Other Ingredients: Fructose, Maltose, Sorbitol, Natural Flavors, Stearic and Malic Acids.Contains ingredients from milk and egg.
Brand name products often contain multiple ingredients. To read detailed information about each ingredient, click on the link for the individual ingredient shown above.
Below is general information about the effectiveness of the known ingredients contained in the product Transfer Factor Chewable Tri Factor Formula. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product Transfer Factor Chewable Tri Factor Formula. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
LIKELY SAFE ...when used orally and appropriately. There are no reports of significant toxicity in multiple human trials (4901,4903,4904,4905,4906,4907,4908,4909,36980,36988) (36992,36995,36998,37000,92412,92413,92415,101799,111136,111138) (111139,114817). However, bovine colostrum is derived from animals, and there is some concern about contamination with diseased animal parts (1825). So far, there are no reports of disease transmission to humans due to use of contaminated bovine colostrum.
POSSIBLY SAFE ...when used rectally and appropriately, short-term. Bovine colostrum has been used with apparent safety when administered as a 10% enema twice weekly for up to 4 weeks (9730). ...when used intravaginally and appropriately, short-term. Bovine colostrum has been used with apparent safety when administered vaginally as a tablet twice weekly for up to 6 months, as a 1% cream once daily for up to 15 days, or as a gel containing 2.3% bovine colostrum daily for 12 weeks (92424,98819,101794). There is insufficient reliable information available about the safety of bovine colostrum when used topically.
CHILDREN: POSSIBLY SAFE
when used orally and appropriately, short-term.
Bovine colostrum has been used with apparent safety in children for 1-3 months (92420,95924,101797,114819). There is insufficient reliable information available about the safety of long-term use of bovine colostrum in children.
CHILDREN: POSSIBLY UNSAFE
when used enterally in very preterm infants in the first few weeks of life.
Enterally, bovine colostrum added to breastmilk for very preterm infant feeding in the first 14 days of life has been associated with a higher rate of periventricular leukomalacia when compared with preterm formula added to breastmilk in one clinical trial (114816). Orally, the addition of bovine colostrum to breastmilk for very preterm infant feeding resulted in infants requiring more calcium and phosphate supplementation to maintain acceptable blood levels when compared with conventional fortifier in one clinical trial (114822).
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
POSSIBLY SAFE ...when used orally or parenterally and appropriately. Human-derived transfer factor has been used safely in studies lasting up to 2 years (3062,7562,7797,7798) and bovine-derived transfer factor has been safely used in small studies lasting up to 3 months (1445,1507). Some evidence suggests these products are safe; however, some preparations are derived from animals and there is concern about contamination with diseased animal parts (see Adverse Reactions) (1825). There are no reports of disease transmission to humans due to use of contaminated bovine transfer factor.
CHILDREN: POSSIBLY SAFE
when used orally or parenterally and appropriately.
Human-derived transfer factor administered subcutaneously has been used safely for up to 6 years (7794). Oral bovine transfer factor has been used safely for up to 6 months (350).
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Transfer Factor Chewable Tri Factor Formula. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Below is general information about the adverse effects of the known ingredients contained in the product Transfer Factor Chewable Tri Factor Formula. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General ...Orally, bovine colostrum is well tolerated.
Endocrine ...Enterally, the addition of bovine colostrum to breastmilk for very preterm infant feeding resulted in infants requiring more calcium and phosphate supplementation to maintain acceptable blood levels when compared with conventional fortifier in one clinical trial (114822).
Gastrointestinal ...Orally, bovine colostrum has caused nausea and vomiting in an individual with HIV-related cryptosporidiosis (4905). In clinical trials of bovine colostrum, bloating, nausea, diarrhea, and unsettled stomach have been reported as mild in nature by a few patients (92414,101792) with a similar rate of occurrence as those taking a whey-based control (114819).
Hematologic ...Orally, bovine colostrum has caused decreased serum hematocrit in HIV patients treated for infectious diarrhea (4905).
Hepatic ...Orally, bovine colostrum has caused elevated liver function tests in HIV patients treated for infectious diarrhea (4905).
Immunologic ...Topically, there is a case report of anaphylaxis, urticaria, and itching related to bovine colostrum (101793).
Neurologic/CNS ...Enterally , bovine colostrum has been associated with increased risk of periventricular leukomalacia in very preterm infants. Specifically, in a large, multi-center, clinical study conducted in 7 neonatal intensive care units in China, 5 cases of periventricular leukomalacia (PVL), diagnosed with magnetic resonance imaging, were reported among the 155 infants fed bovine colostrum supplemented breastmilk until postnatal day 14, while no cases were reported among the 181 infants receiving preterm formula supplemented breastmilk. Three of the 5 infants with PVL were fed small volumes of bovine colostrum (less than 10 mL/kg daily) while 2 were fed larger volumes of bovine colostrum (18-35 mL/kg daily). in addition to preterm formula (114816).
Renal ...Enterally, bovine colostrum added to breastmilk for infant feeding until postnatal day 14 among very preterm infants has been associated with higher blood urea nitrogen levels by about 3 mg/dL when compared with preterm formula added to breastmilk (114816).
Other ...Theoretical adverse effects to bovine colostrum include an allergic reaction in individuals allergic to bovine milk products. There is also some concern that bovine colostrum that is obtained from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be unsafe, however, there is no research indicating that colostrum can be contaminated with the BSE-causing prion. Countries where BSE has been reported include Great Britain, France, The Netherlands, Portugal, Luxembourg, Ireland, Switzerland, Oman, and Belgium (1825). Until more is known, tell patients to avoid these products unless country of origin can be determined. Patients should avoid products that are produced in countries where BSE has been found.
General
...Orally or parenterally, transfer factor seems to be well tolerated (350,1445,1507,3062,3063,7562,7794,7797,7798,7799,78668,78669,78702,78714,78774,78796).
Adverse effects may include fever (1507). Parenterally, transfer factor can cause nausea, fatigue, and tenderness, pain, and swelling at the injection site (3062,7562,7799,78809). Orally, severe acne has been reported (78820).
There is some concern that bovine-derived transfer factor that is produced from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be contaminated with diseased tissue. Countries where BSE has been reported include Great Britain, France, the Netherlands, Portugal, Luxembourg, Ireland, Switzerland, Oman, and Belgium (1825). However, there have been no reports of BSE transfer to humans from contaminated transfer factor products. Until more is known, tell patients to avoid these products unless country of origin can be determined. Patients should avoid products that are produced in countries where BSE has been found.
Dermatologic ...Orally, transfer factor may cause severe acne in some patients (78820).
Gastrointestinal ...Parenterally, nausea has been reported in a patient following treatment with transfer factor (78809)
Musculoskeletal ...Parenterally, transfer factor may cause tenderness, pain, and swelling at the injection site (3062,7562,7799,78809).
Neurologic/CNS ...Parenterally, fatigue has been reported for up to 4 hours in a patient using transfer factor (78789).
Other
...Orally or parenterally, transfer factor may cause fever (1507,78789,78809).
There is some concern that bovine-derived transfer factor that is produced from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be contaminated with diseased tissue. Countries where BSE has been reported include Great Britain, France, the Netherlands, Portugal, Luxembourg, Ireland, Switzerland, Oman, and Belgium (1825). However, there have been no reports of BSE transfer to humans from contaminated transfer factor products. Until more is known, tell patients to avoid these products unless country of origin can be determined. Patients should avoid products that are produced in countries where BSE has been found.
